Filing Details

Accession Number:
0001093557-20-000323
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-12-03 17:11:50
Reporting Period:
2020-12-01
Accepted Time:
2020-12-03 17:11:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1093557 Dexcom Inc DXCM Surgical & Medical Instruments & Apparatus (3841) 330857544
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1286858 R Kevin Sayer 6340 Sequence Drive
San Diego CA 92121
Chairman, Ceo & President Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-12-01 1,557 $319.76 127,190 No 4 S Direct
Common Stock Disposition 2020-12-01 3,327 $321.19 123,863 No 4 S Direct
Common Stock Disposition 2020-12-01 3,970 $322.24 119,893 No 4 S Direct
Common Stock Disposition 2020-12-01 3,119 $323.45 116,774 No 4 S Direct
Common Stock Disposition 2020-12-01 1,260 $324.38 115,514 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.
  2. This transaction was executed in multiple trades at prices ranging from $319.29 to $320.13. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
  3. Included in this number are 56,792 unvested restricted stock units, 25,453 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 17,915 of which were granted on March 8, 2019 and shall vest through March 8, 2022, and 13,424 of which were granted on March 8, 2018 and shall vest through March 8, 2021.
  4. This transaction was executed in multiple trades at prices ranging from $320.61 to $321.56. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
  5. This transaction was executed in multiple trades at prices ranging from $321.88 to $322.76. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
  6. This transaction was executed in multiple trades at prices ranging from $322.99 to $323.92. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
  7. This transaction was executed in multiple trades at prices ranging from $324.13 to $324.51. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.